Author: Copley, Hannah C.; Gragert, Loren; Leach, Andrew R.; Kosmoliaptsis, Vasilis
Title: Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level Cord-id: bjhumtjp Document date: 2021_7_19
ID: bjhumtjp
Snippet: Development of adaptive immunity after COVID-19 and after vaccination against SARS-CoV-2 is predicated on recognition of viral peptides, presented on HLA class II molecules, by CD4+ T-cells. We capitalised on extensive high-resolution HLA data on twenty five human race/ethnic populations to investigate the role of HLA polymorphism on SARS-CoV-2 immunogenicity at the population and individual level. Within populations, we identify wide inter-individual variability in predicted peptide presentatio
Document: Development of adaptive immunity after COVID-19 and after vaccination against SARS-CoV-2 is predicated on recognition of viral peptides, presented on HLA class II molecules, by CD4+ T-cells. We capitalised on extensive high-resolution HLA data on twenty five human race/ethnic populations to investigate the role of HLA polymorphism on SARS-CoV-2 immunogenicity at the population and individual level. Within populations, we identify wide inter-individual variability in predicted peptide presentation from structural, non-structural and accessory SARS-CoV-2 proteins, according to individual HLA genotype. However, we find similar potential for anti-SARS-CoV-2 cellular immunity at the population level suggesting that HLA polymorphism is unlikely to account for observed disparities in clinical outcomes after COVID-19 among different race/ethnic groups. Our findings provide important insight on the potential role of HLA polymorphism on development of protective immunity after SARS-CoV-2 infection and after vaccination and a firm basis for further experimental studies in this field.
Search related documents:
Co phrase search for related documents- accessory protein and lung disease: 1, 2, 3
- accessory sars protein and acute infection: 1
- accessory sars protein and lung disease: 1, 2
- acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute infection and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute infection and low capacity: 1, 2
- acute infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
- acute phase and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immunity and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive response and low capacity: 1, 2
- adaptive response and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
- low capacity and lung disease: 1, 2
Co phrase search for related documents, hyperlinks ordered by date